Novo Nordisk is reducing its global workforce by 9,000 employees, roughly 11 percent, amid mounting pressure and intense competition in the burgeoning weight-loss drug market. The layoffs reflect strategic adjustments as the company faces challenges from rivals like Lilly. This move highlights the shifting dynamics in the pharmaceutical industry and the pressures companies encounter to innovate and stay competitive in a rapidly growing sector.